![]() |
|
|
Vol. 293, Issue 2, 351-359, May 2000
Institute of Pharmacology, University of Halle, Halle, Germany
(S.D.); Institute of Pharmacology, University of Cologne, Cologne,
Germany (S.H., C.a.d.S., K.B.); and Knoll AG, Ludwigshafen, Germany
(C.H., M.R.)
Diabetic angiopathy is a serious problem in antidiabetic therapy. We
wanted to investigate whether treatment with the
endothelinA receptor antagonist LU 135252 or with
the angiotensin-converting enzyme inhibitor trandolapril might prevent
angiopathy in long-term type I diabetes mellitus. Six groups of male
Wistar rats were investigated: untreated age-matched control rats,
healthy controls treated with trandolapril (0.3 mg/kg), healthy
controls treated with LU 135252 (100 mg/kg), untreated diabetic rats,
and diabetic rats treated with either trandolapril or LU 135252. Rats
were rendered diabetic by injection of streptozotozin. Duration
of the disease was 6 months. Thereafter, rats were sacrificed, and hearts, kidneys, and a mesenterial loop were removed. Hearts and kidneys were processed histologically; the mesenterial loop was perfused with saline at constant pressure for investigation of microvessels using microvideoangiometry while treated with either 30 mM
KCl, 1 µM acetylcholine, or 1 µM sodium nitroprusside. All diabetic
rats developed hyperglycemia without differences among these three
groups. Diabetic rats exhibited marked anemia, which was significantly
antagonized by both treatments. The heart capillaries/muscle fibers
ratio was decreased significantly in diabetic animals, which was
prevented fully by both treatments. Renal glomerular diameter was
increased in diabetic rats. This was significantly antagonized by LU
135252 but not by trandolapril. Deposition of homogeneous eosinophilic
material within the glomeruli was nearly completely prevented by LU
135252. The acetylcholine-induced vasodilation in mesenteric
microvessels was significantly attenuated in diabetic rats, which was
significantly antagonized by both treatments. We conclude that both
angiotensin and endothelin seem to contribute to the development of
diabetic angiopathy and that, in addition to angiotensin-converting
enzyme inhibition, blockade of endothelinA receptors may be
an interesting new approach to antiangiopathic therapy.
This article has been cited by other articles:
![]() |
M. Wendel, L. Knels, W. Kummer, and T. Koch Distribution of Endothelin Receptor Subtypes ETA and ETB in the Rat Kidney J. Histochem. Cytochem., November 1, 2006; 54(11): 1193 - 1203. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jesmin, S. Zaedi, N. Yamaguchi, S. Maeda, I. Yamaguchi, K. Goto, and T. Miyauchi Effects of dual endothelin receptor antagonist on antiapoptotic marker bcl-2 expression in streptozotocin-induced diabetic rats. Experimental Biology and Medicine, June 1, 2006; 231(6): 1034 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Pfab, C. Thone-Reineke, F. Theilig, I. Lange, H. Witt, C. Maser-Gluth, M. Bader, J.-P. Stasch, P. Ruiz, S. Bachmann, et al. Diabetic Endothelin B Receptor-Deficient Rats Develop Severe Hypertension and Progressive Renal Failure J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1082 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Portik-Dobos, A. K. Harris, W. Song, J. Hutchinson, M. H. Johnson, J. D. Imig, D. M. Pollock, and A. Ergul Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R435 - R441. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sorokin and D. E. Kohan Physiology and pathology of endothelin-1 in renal mesangium Am J Physiol Renal Physiol, October 1, 2003; 285(4): F579 - F589. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dhein, A. Kabat, A. Olbrich, P. Rosen, H. Schroder, and F.-W. Mohr Effect of Chronic Treatment with Vitamin E on Endothelial Dysfunction in a Type I in Vivo Diabetes Mellitus Model and in Vitro J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 114 - 122. [Abstract] [Full Text] |
||||